Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Liminatus Pharma (Nasdaq: LIMN) announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026.

Rhea-AI Summary

Liminatus Pharma (Nasdaq: LIMN) announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The move enables LIMN shares to continue trading on Nasdaq under the existing ticker.

The Nasdaq Hearings Panel granted Liminatus an extension until September 3, 2026 to regain compliance with Nasdaq’s minimum bid price requirement. The company intends to take necessary actions within this period, and its stock will continue trading on the Nasdaq Capital Market, subject to ongoing compliance with the Panel’s decision and other Nasdaq continued listing standards.

Positive

• Extension to regain bid price compliance until September 3, 2026
• Shares continue trading on Nasdaq Capital Market under ticker LIMN
• Regained time window supports ongoing corporate and clinical development plans

Negative

• Transfer from Nasdaq Global Market to Capital Market reflects non-compliance status
• Company remains out of compliance with minimum bid price requirement
• Continued listing depends on meeting Panel conditions by September 3, 2026

Argus Aug 13 session 170 alerts

+32.53% close to close 864.2x rel. volume Open Argus

Details

News Market Reaction – LIMN

+77.8% Peak in 40 min

$13.99M Market Cap

On Aug 13, the day this news came out, LIMN closed 32.53% above the previous close. Argus tracked a peak move of +77.8% during that session. Our momentum scanner recorded 170 alerts for this stock that day. Relative volume reached 864.2x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 13 session.

Market Context

On Aug 13, the day this news came out, the stock closed 32.5% above the previous close. A 30.99% 24-...

Analysis

On Aug 13, the day this news came out, the stock closed 32.5% above the previous close. A 30.99% 24-hour reaction followed LIMN’s May 21 merger announcement. The current listing transfer and compliance extension should be read alongside that history, while low short positioning remained a sourced constraint on squeeze-related interpretation.

Key Figures

Transfer Effective Date: August 4, 2026 Compliance Deadline: September 3, 2026 Nasdaq Listing Tiers: 3 listing tiers

Transfer Effective Date

August 4, 2026

Transfer from Nasdaq Global Market to Nasdaq Capital Market

Compliance Deadline

September 3, 2026

Deadline to demonstrate compliance with the Bid Price Rule

Nasdaq Listing Tiers

3 listing tiers

Nasdaq Capital Market description

Historical Context

5 past events · Latest: Jun 30

5 events

1. Jun 30

   merger amendment

   24h Move

   +4.0%

   Merger terms were amended to facilitate closing before stockholder approval.

2. Jun 03

   warrant exercise

   24h Move

   -22.2%

   Investors exercised existing warrants while receiving new warrants at a lower exercise price.

3. May 21

   delisting notification

   24h Move

   -31.1%

   Nasdaq issued a delisting notice citing market value listing deficiencies.

4. May 21

   merger agreement

   24h Move

   +31.0%

   Liminatus signed a definitive agreement to acquire InnocsAI.

5. Mar 17

   clinical trial plan

   24h Move

   -2.5%

   The company announced plans to initiate a Phase 1 trial for IBA101.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq capital market, nasdaq hearings panel, minimum bid price requirement

3 terms

nasdaq capital market regulatory

"transferred from the Nasdaq Global Market to the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

nasdaq hearings panel regulatory

"that the Nasdaq Hearings Panel (the “Panel”) has granted the Company"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

minimum bid price requirement regulatory

"compliance with Nasdaq’s minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement.

The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, “LIMN.” The Nasdaq Capital Market is one of Nasdaq’s three listing tiers.

In addition, the Panel has granted the Company’s request for an extension to demonstrate compliance with the applicable minimum bid price requirement. Under the Panel’s decision, the Company has until September 3, 2026 to demonstrate compliance with the Bid Price Rule.

The Company intends to take the actions necessary to regain compliance with the minimum bid price requirement within the period granted by the Panel. The Company’s common stock will continue to trade on the Nasdaq Capital Market during this period, subject to the Company’s compliance with the Panel’s decision and other applicable Nasdaq continued listing requirements.

“We are pleased to have completed the transfer to the Nasdaq Capital Market and appreciate the Panel providing the Company additional time to demonstrate compliance with the minimum bid price requirement,” said Scott Dam, Chief Financial Officer of Liminatus Pharma. “Maintaining our Nasdaq listing remains an important priority as we continue executing on our corporate and clinical development strategy.”

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The Company’s development portfolio includes IBA101, a humanized anti-CD47 monoclonal antibody being developed as a next-generation immune-modulating cancer therapy, together with additional therapeutic assets acquired through the Company’s strategic transactions.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing and effectiveness of actions taken to regain compliance, the Company’s continued listing on the Nasdaq Capital Market, and the Company’s corporate and clinical development plans. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no assurance that the Company will regain compliance with the minimum bid price requirement within the period granted by the Panel or maintain compliance with other applicable Nasdaq listing requirements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For more information, please contact:

Chris Kim, Chief Executive Officer
chris@liminatus.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Liminatus Pharma (LIMN) announce about its Nasdaq listing on August 13, 2026?

Liminatus Pharma announced a transfer of its common stock to the Nasdaq Capital Market and an extension to regain minimum bid price compliance. According to Liminatus Pharma, LIMN will keep trading on Nasdaq under its existing ticker during the granted compliance period.

Why was Liminatus Pharma (LIMN) transferred from Nasdaq Global Market to Nasdaq Capital Market?

Liminatus Pharma’s stock was transferred to the Nasdaq Capital Market to allow continued Nasdaq trading while it addresses the minimum bid price requirement. According to Liminatus Pharma, this move keeps LIMN listed as the company works toward regaining full bid price compliance.

What is the deadline for Liminatus Pharma (LIMN) to regain Nasdaq minimum bid price compliance?

Liminatus Pharma has until September 3, 2026 to demonstrate compliance with Nasdaq’s minimum bid price rule. According to Liminatus Pharma, this deadline was set by the Nasdaq Hearings Panel as part of its extension decision.

Will Liminatus Pharma (LIMN) shares continue trading on Nasdaq during the compliance extension period?

Yes, LIMN shares will continue trading on the Nasdaq Capital Market during the extension period. According to Liminatus Pharma, ongoing trading is subject to compliance with the Panel’s decision and other applicable Nasdaq continued listing requirements.

What does the Nasdaq Capital Market transfer mean for Liminatus Pharma (LIMN) shareholders?

The transfer keeps LIMN shares listed on Nasdaq but on a different tier while the company addresses bid price compliance. According to Liminatus Pharma, maintaining a Nasdaq listing remains an important priority as it pursues its corporate and clinical development strategy.

How does Liminatus Pharma plan to regain compliance with Nasdaq’s minimum bid price rule?

Liminatus Pharma stated it intends to take the actions necessary to regain compliance within the Panel’s timeframe. According to Liminatus Pharma, the company aims to meet the minimum bid price requirement by the September 3, 2026 deadline.